This article is more than 5 years old. Information may no longer be current.
Positive ongoing results in phase 1/2 trial in noninfectious uveitis
Seven out of eight patients with noninfectious uveitis receiving a suprachoroidal injection of triamcinolone acetonide achieved clinically meaningful reduction in retinal thickness at 8 weeks, according to a press release from Clearside Biomedical Inc.
Five of these seven patients experienced a reduction in retinal thickness to below 310 microns, which represents the maximum retinal thickness for approximately 95% of the population with normal retinas, according to the press release.
In addition, all eight patients showed clinically meaningful improvement of five or more letters in best-corrected visual acuity at week 8, while five improved by at least 15 letters at week 8.
According to Clearside, the suprachoroidal injection of triamcinolone acetonide appeared generally well tolerated in all eight patients with noninfectious uveitis. No patient in the study experienced a clinically meaningful increase in intraocular pressure.